title: Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer.
abstract: Non-small cell lung cancer (NSCLC) is the first cause of cancer related death in the world. Biomarkers to predict the relapse and drug resistance could be extremely useful for a clinical doctor to monitor high risk patients and select rational regimen. miRNAs play an important role in lung cancer and detection samples are relatively easy to be obtained, miRNAs could become a promising means of comprehending the oncogenesis and pathogenesis of lung cancer. This study aimed to investigate the function of miR-145 to work as a biomarker in NSCLC. miR-145 expression level in 48 NSCLC tumor tissues and their matched normal tissues were detected by qRT-PCR. miR-145 in 18 paraffin-embedded samples underwent chemotherapy and were assessed by in situ hybridization (ISH). Here we show that miR-145 was down-regulated in NSCLC tissues; down-regulation of miR-145 was correlated with late clinical stage and poorly differentiated carcinoma, and, low expression level of miR-145 could also predict chemotherapy resistance and shorter disease-free survival (DFS). These findings indicated that miR-145 expression may be a useful prognostic marker that could be used for predicting poor differentiation, chemo-resistance and shore DFS.
authors: Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China; Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing , 210029 Jiangsu Province, China.
authors: Hua
authors: H
authors: Shen
authors: Department of Clinical Laborotory, First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei Province, China. Electronic address: docsjx@163.com.
authors: Jianxin
authors: J
authors: Shen
authors: Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China; Nanjing Ninggao Individual Medical Technology Innovation Center Ltd, Nanjing, 210029 Jiangsu Province, China.
authors: Lin
authors: L
authors: Wang
authors: Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China; Nanjing Ninggao Individual Medical Technology Innovation Center Ltd, Nanjing, 210029 Jiangsu Province, China.
authors: Zhumei
authors: Z
authors: Shi
authors: Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China; Nanjing Ninggao Individual Medical Technology Innovation Center Ltd, Nanjing, 210029 Jiangsu Province, China.
authors: Min
authors: M
authors: Wang
authors: Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China; Nanjing Ninggao Individual Medical Technology Innovation Center Ltd, Nanjing, 210029 Jiangsu Province, China.
authors: Bing-Hua
authors: BH
authors: Jiang
authors: Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China; Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing , 210029 Jiangsu Province, China. Electronic address: shuyongqian1999@126.com.
authors: Yongqian
authors: Y
authors: Shu
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology*; D002454:Cell Differentiation / Q000235:genetics*; D018572:Disease-Free Survival; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology*; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism
chemical_list: C541010:MIRN145 microRNA, human; D035683:MicroRNAs
keywords: NSCLC; Pathological differentiation; Prognosis; miR-145